Key points are not available for this paper at this time.
Lifelong administration of colchicine is the mainstay of treatment for familial Mediterranean fever (FMF), whereas canakinumab, a monoclonal antibody that blocks the effects of interleukin (IL)-1β, can be used in case of colchicine resistance or its poor tolerability.
Barsuk et al. (Sun,) studied this question.